Investigating new treatments for glioblastomas using microtubule targeting agents
Differential response of glioblastomas to microtubule targeting agents
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10897299
This study is looking at new treatments for glioblastoma, an aggressive brain cancer, to see how well they can get into the brain and work differently than current options, with the hope of finding better ways to help patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10897299 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new microtubule targeting agents (MTAs) that can effectively treat glioblastomas (GBM), a type of aggressive brain cancer. The study aims to understand how these new agents can cross the blood-brain barrier and their unique mechanisms of action compared to existing treatments. By using advanced technologies like live-cell imaging and artificial intelligence, researchers will observe how GBM cells respond to these agents in both laboratory cultures and preclinical mouse models. The goal is to identify effective treatment strategies that could improve outcomes for patients with GBM.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from new therapeutic approaches.
Not a fit: Patients with other types of brain tumors or those who do not have glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma patients, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using novel MTAs for cancer treatment, but this specific approach is relatively novel and untested in the context of glioblastomas.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STELLA, NEPHI — UNIVERSITY OF WASHINGTON
- Study coordinator: STELLA, NEPHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.